ÂÜÀòÂÒÂ×

Darwin Yang is a skilled scientist with extensive experience in chemical and biomolecular engineering. Currently serving as a Principal Scientist at Intellia Therapeutics, Inc. since March 2022, Darwin previously held the role of Senior Scientist at Rewrite Therapeutics from November 2020 to February 2022. Prior to that, Darwin was a Graduate Student Researcher in the Landry Lab at the University of California, Berkeley, from August 2015 to October 2020, where significant contributions included engineering carbon nanotube-based neurosensors and developing assays for biomolecule competitive adsorption. Additionally, Darwin worked as a Graduate Student Instructor, facilitating undergraduate learning in various chemical engineering topics. Early career experience includes a summer research internship at the National Cancer Institute in 2013. Darwin obtained a Ph.D. in Chemical and Biomolecular Engineering from the University of California, Berkeley, in 2020, after earning a Bachelor's Degree in Chemical Engineering from Carnegie Mellon University in 2015.